Skip to content

Influence of Sedation Strategies on Hospital LOS and ICU LOS in Patients Cardiac Surgery

Influence of Sedation Strategies on Hospital LOS and ICU LOS in Patients After Cardiac Surgery With Cardiac Pulmonary Bypass. Comparison of Propofol-based, Dexmedetomidine-based Sedation or Their Combination.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05809518
Acronym
LOS
Enrollment
194
Registered
2023-04-12
Start date
2017-01-01
Completion date
2019-12-31
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation Complication

Keywords

cardiac surgery, ICU sedation, hospital LOS, ICU LOS, vasopressors, postoperative sedation

Brief summary

Preoperative, intraoperative and postoperative management of the patient are some of the main stages that can affect the hospital LOS and ICU LOS. Experience on the evidence-based approach and the progressive guidelines implementation of recommendations, the issue of the choice of drugs for sedation in the family and their impact on the length of stay in the intensive care unit and the length of hospitalization remain unsolved.

Detailed description

Optimization of sedation regimes can become one of the factors that will help to reduce the length of hospital and ICU stay. The purpose of the study is to track is there a relationship between the drug for sedation and the length of stay of patients in the intensive care unit and in hospital treatment.

Interventions

sedation after cardiac surgery

DRUGDexmedetomidine injection

sedation after cardiac surgery

sedation after cardiac surgery

Sponsors

Anesthesia Research Group UA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Multi vascular lesions of the coronary arteries according to coronary angiography; * Heart valve damage was confirmed by heart ultrasound, which is subject to surgical correction (aortic stenosis of III degree with a gradient on the aortic valve of more than 42 mmHg, aortic insufficiency III, mitral valve stenosis II-III, mitral regurgitation II-III) * Patient consent to participate in the study; * Women who have a negative pregnancy test and use effective contraception throughout the study and for 3 weeks after its completion, or women who are unable to have children (women who have undergone a hysterectomy (removal of the uterus) or tubal ligation, women with a clinical diagnosis of infertility) or are menopausal for more than 1 year (absence of menstruation for at least 12 months). Adequate methods of contraception include: surgical sterilization, double barrier method of contraception, local contraception;

Exclusion criteria

* Refusal to participate; * Hypersensitivity to propofol, dexmedetomidine; * Prolonged mechanical ventilation in case of surgical complications (bleeding, inadequate perfusion of the myocardium); * Occurred ischemic stroke; * History of the ischemic stroke; * History of the neurodegenerative diseases; * History of the mental disorders; * Use of neuroleptics, antidepressants for the last 5 years; * History of the cardiac surgery in the past; * Patients with chronic pulmonary disease (GOLD 3-4) * Patients with asthma (moderate or severe), * Participation in any other clinical trial; * Gastric or duodenal ulcer with risk of bleeding; * Chronic renal failure (ClCr less than 50 ml / h) * Acute renal failure that occurred during surgery (ClCr less than 50 ml / h, or a decrease in the rate of diuresis to 0.1 ml / h in the first 4 hours after surgery and does not respond to diuretic therapy) * Chronic hepatic insufficiency if there are laboratory signs of hypo coagulation without the use of anticoagulant therapy (INR\> 1.5) * If the patient has not stopped taking anticoagulants or antiplatelet agents in the preoperative period: warfarin 5 days before surgery, clopidogrel 5-7 days before surgery, xarelto / pradaxa 3 days before surgery), * History of the hematological disease; * Alcohol abuse in the anamnesis (3-4 times a week). * Condition after chemotherapy; Pregnancy, lactation.

Design outcomes

Primary

MeasureTime frameDescription
hospital LOSfrom admission to discharge ( up to 20 days)measure at days
ICU LOSbefore discharging from ICU to the ward ( up to 7 days)measure at days

Secondary

MeasureTime frameDescription
difference in ICU LOS in patients with vasopressors and without vasopressorsbefore discharging from ICU to the ward ( up to 7 daysmeasure at days

Other

MeasureTime frameDescription
difference in hospital LOS in patients with vasopressors and without vasopressorsfrom admission to discharge ( up to 20 days)measure at days

Countries

Ukraine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026